-
公开(公告)号：US20160095910A1
公开(公告)日：2016-04-07
申请号：US14854224
申请日：2015-09-15
IPC分类号： A61K39/00 , C07K14/50 , C07K14/495
摘要： The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.
摘要翻译： 本公开内容提供了用作免疫调节剂的合成免疫原性蛋白，以增强对包含但不限于自身抗原的共轭蛋白或含有抗原的哺乳动物免疫反应，否则其抗原性差。 本公开的嵌合免疫原性蛋白质可用于治疗许多疾病，包括但不限于癌症，感染性疾病，自身免疫疾病，过敏症以及涉及或受哺乳动物宿主的免疫应答影响的任何临床适应症。
-
公开(公告)号：US20200297827A1
公开(公告)日：2020-09-24
申请号：US16843118
申请日：2020-04-08
IPC分类号： A61K39/00 , C07K14/475 , C07K14/485 , C07K14/495 , C07K14/50
摘要： The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.
-
公开(公告)号：US10736948B2
公开(公告)日：2020-08-11
申请号：US14854224
申请日：2015-09-15
IPC分类号： A61K39/00 , C07K14/475 , C07K14/485 , C07K14/495 , C07K14/50
摘要： The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.
-
公开(公告)号：US07238349B1
公开(公告)日：2007-07-03
申请号：US10088632
申请日：2000-09-27
申请人： Erik D'Hondt , Norbert Hehme
发明人： Erik D'Hondt , Norbert Hehme
IPC分类号： A61K35/76
CPC分类号： C12N7/00 , A61K39/12 , A61K39/145 , A61K2039/5252 , A61K2039/54 , A61K2039/543 , A61K2039/55505 , C07K14/005 , C12N2760/16122 , C12N2760/16151 , C12N2760/16222 , C12N2760/16234 , C12N2760/16251
摘要： The invention provides a monovalent influenza vaccine comprising a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, in combination with an aluminium adjuvant. The invention also provides vaccine kits comprising a combination of a parenteral and a mucosal influenza vaccine, wherein the combined dose of antigen is no more than the conventional antigen dose. Also provided are methods for preparing the vaccines.
摘要翻译： 本发明提供了一种单价流感疫苗，其包含与大流行性流感相关的流感病毒毒株的低剂量的来自卵的流感病毒抗原或与大肠杆菌爆发相关联的潜在的铝佐剂。 本发明还提供包含肠胃外和粘膜流感疫苗的组合的疫苗试剂盒，其中抗原的组合剂量不超过常规抗原剂量。 还提供了制备疫苗的方法。
-
公开(公告)号：US20070141078A1
公开(公告)日：2007-06-21
申请号：US11487769
申请日：2006-07-17
申请人： Erik D'Hondt , Norbert Hehme , Emmanuel Hanon , Jean Stephenne
发明人： Erik D'Hondt , Norbert Hehme , Emmanuel Hanon , Jean Stephenne
IPC分类号： A61K39/395 , A61K39/12
CPC分类号： C12N7/00 , A61K39/12 , A61K39/145 , A61K2039/5252 , A61K2039/54 , A61K2039/543 , A61K2039/55505 , C07K14/005 , C12N2760/16122 , C12N2760/16151 , C12N2760/16222 , C12N2760/16234 , C12N2760/16251
摘要： The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol or a tocopherol such as alpha tocopherol, and an emulsifying agent.
摘要翻译： 本发明涉及用于免疫流感病毒的单价流感疫苗制剂和疫苗接种方案，它们在医学中的用途，特别是它们在增强对各种抗原的免疫应答中的用途以及制备方法。 特别地，本发明涉及包含流感病毒抗原或其抗原制品的单价流感免疫原性组合物，该流感病毒抗原或其抗原制品与流感大流行爆发相关或具有与大流行性流感相关联的流感病毒株， 水乳剂佐剂，其包含可代谢的油，固醇或生育酚如α-生育酚和乳化剂。
-
公开(公告)号：US20050112144A1
公开(公告)日：2005-05-26
申请号：US10878094
申请日：2004-06-28
申请人： Erik D'Hondt
发明人： Erik D'Hondt
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5252 , A61K2039/55505 , A61K2039/55572 , A61K2039/70 , C12N2730/10134 , C12N2770/32434 , C12N2770/32451 , C12N2770/32463 , C12N2770/32471
摘要： A process for the production of inactivated Hepatitis A virus substantially free of host cell contamination is described, the process comprising: a)culturing Hepatitis A virus and harvesting a Hepatitis A preparation; b) treating said Hepatitis A preparation with a protease; and thereafter c) separating intact virus from protease-digested material; d) inactivating said virus. Also described are vaccines comprising the inactivated Hepatitis A virus, preferably in combination with strong adjuvants.
摘要翻译： 描述了生产基本上不含宿主细胞污染的灭活的甲型肝炎病毒的方法，该方法包括：a）培养甲型肝炎病毒并收获甲型肝炎制剂; b）用蛋白酶处理所述甲型肝炎制剂; 然后c）将完整病毒与蛋白酶消化的材料分离; d）使所述病毒失活。 还描述了包含灭活的甲型肝炎病毒的疫苗，优选与强佐剂组合。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.036 秒)
